Evidence map›Paper›PMID 42653176›Full record

ReviewInternational journal of molecular sciences2026

Learning from Biodegradable Coronary Stents: Future Directions for TPVR Biodegradable Stents.

Zhaoyang Ye, Nina Sophie Pommert, David Meier, Stephanie L Sellers, Jakob Christoph Voran, Oliver J Müller, Derk Frank, Tim Attmann, Gregor Warnecke, Thomas Puehler and 1 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhaoyang YeDepartment of Cardiac Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.ORCID 0009-0004-9622-980X
Nina Sophie PommertGerman Centre for Cardiovascular Research (DZHK), Partner Site North, 20251 Hamburg, Germany.
David MeierDepartment of Cardiology, Lausanne University Hospital and University of Lausanne, 1015 Lausanne, Switzerland.ORCID 0000-0002-5524-5844
Stephanie L SellersCentre for Cardiovascular Innovation, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Jakob Christoph VoranGerman Centre for Cardiovascular Research (DZHK), Partner Site North, 20251 Hamburg, Germany.ORCID 0009-0000-4547-9260
Oliver J MüllerGerman Centre for Cardiovascular Research (DZHK), Partner Site North, 20251 Hamburg, Germany.ORCID 0000-0001-8223-2638
Derk FrankGerman Centre for Cardiovascular Research (DZHK), Partner Site North, 20251 Hamburg, Germany.ORCID 0000-0001-7561-075X
Tim AttmannDepartment of Cardiac Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.ORCID 0000-0002-5991-2106
Gregor WarneckeDepartment of Cardiac Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.ORCID 0000-0002-4689-5714
Thomas PuehlerGerman Centre for Cardiovascular Research (DZHK), Partner Site North, 20251 Hamburg, Germany.ORCID 0000-0002-4990-1892
Georg LutterDepartment of Cardiac Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.ORCID 0000-0002-9145-3210

Funding

German Centre for Cardiovascular Research 81Z0700213
6 · The paper itself

Abstract

Bioresorbable stents (BRS) have been explored in cardiovascular intervention to provide temporary mechanical support while reducing long-term foreign material. The coronary experience has shown both the potential and the limitations of this strategy. First-generation polymeric stents demonstrated feasibility but were limited by thick struts, insufficient radial strength, delayed healing, and increased scaffold thrombosis. In contrast, metallic bioresorbable platforms improved mechanical performance, but each material system still faces trade-offs between strength, degradation rate, and biological response. Transcatheter pulmonary valve replacement (TPVR) may represent a clinically meaningful setting for renewed BRS development. Patients with congenital heart disease often require repeated pulmonary valve interventions over a lifetime, and permanent metallic frames may increase cumulative implant burden and complicate future treatment. However, TPVR imposes distinct requirements, including large-diameter expansion, stable anchoring, fatigue resistance, controlled degradation, and leaflet-frame integration. This review summarizes the lessons learned from coronary BRS, discusses material considerations for TPVR-oriented stent design, and evaluates current preclinical evidence for bioresorbable and regenerative pulmonary valve platforms. Particular attention is given to magnesium-zinc alloys as a tunable material strategy for future bioresorbable TPVR frames. Although direct evidence for fully bioresorbable metallic TPVR devices remains limited, this approach provides a rational framework for next-generation pulmonary valve intervention.

Indexed as

Absorbable ImplantsHeart Valve Prosthesis ImplantationPulmonary ValveStentsAnimalsBiocompatible MaterialsHumansBiocompatible Materialsbiodegradable metalbiodegradable stentbioresorbable stentcoronary bioresorbable stentmagnesium–zinc alloyright ventricular outflow tracttissue-engineered heart valvetranscatheter pulmonary valve replacement

Identifiers

PMID42653176
PMCPMC13513013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.